Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Bull Exp Biol Med ; 177(2): 225-230, 2024 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-39093470

RESUMO

Data on the participation of microbiota in the development of Parkinson's disease allow us to discuss the ability of bacterial preparations to influence the processes leading to neurodegeneration. We studied the effect of oral administration of Limosilactobacillus fermentum U-21 lyophilisate on a model of Parkinson's disease in rats induced by combined intranigral injection of LPS and systemic administration of paraquat. The toxins significantly increased the number of missteps in the "narrowing beam walking" test, but a tendency to a decrease in this parameter was shown after treatment with U-21. It should be noted that U-21 did not reduce the neuronal death in the substantia nigra, but mitigated the inflammatory glial response, decreased the accumulation of phosphorylated α-synuclein and complement protein C3. Our study demonstrated the efficiency of the combined model of parkinsonism and reduction of proinflammatory changes under the influence of pharmabiotic without changes in the nigral neuronal death and motor deficits.


Assuntos
Modelos Animais de Doenças , Lipopolissacarídeos , Substância Negra , alfa-Sinucleína , Animais , Ratos , alfa-Sinucleína/metabolismo , Masculino , Substância Negra/efeitos dos fármacos , Substância Negra/metabolismo , Substância Negra/patologia , Lipopolissacarídeos/farmacologia , Lipopolissacarídeos/toxicidade , Paraquat , Doença de Parkinson/patologia , Doença de Parkinson/tratamento farmacológico , Doença de Parkinson/metabolismo , Ratos Wistar , Complemento C3/metabolismo , Doenças Neuroinflamatórias/patologia , Doenças Neuroinflamatórias/tratamento farmacológico
2.
Probiotics Antimicrob Proteins ; 12(3): 973-979, 2020 09.
Artigo em Inglês | MEDLINE | ID: mdl-31677091

RESUMO

Today, a number of studies conclusively show that certain bacterial strains, mainly from the genera Lactobacillus and Bifidobacterium, influence the functioning of the central nervous system, leading to changes in beahvior, nociception and the cognitive abilities of humans and animals. Such strains serve as the basis for developing probiotics with a curative potential for the central nervous system - psychobioitcs. However, the question of how to find such strains and which criteria to use for their selection remains unanswered. Some compounds produced by bacteria, such as gamma-aminobutyric acid (GABA), the main inhibitory neurotransmitter of the central nervous system, are potential mediators between bacterial cells and the host. Previously, we established that some species of Lactobacillus and Bifidobacterium are capable of producing GABA. We presumed that GABA-producing Lactobacillus and Bifidobacterium strains are great candidates to use as psychobiotics. Therefore, we selected the strains Lactobacillus plantarum 90sk and Bifidobacterium adolescentis 150 as efficient GABA producers. The goal of this work was to assess the probiotic properties of the selected strains as well as their antidepressive effects in mice. We established that the ingestion of the probiotic composition based on the selected strains by BALB/c mice for 2 weeks reduced depressive-like behavior in the forced swimming test; the effect was similar to that of fluoxetine.


Assuntos
Antidepressivos/administração & dosagem , Bifidobacterium adolescentis/metabolismo , Lactobacillus plantarum/metabolismo , Probióticos/administração & dosagem , Ácido gama-Aminobutírico/biossíntese , Animais , Masculino , Camundongos , Camundongos Endogâmicos BALB C
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA